Skip to main content
. 2017 Aug 7;14(4):3233–3238. doi: 10.3892/etm.2017.4893

Figure 5.

Figure 5.

Stratified analysis of the maximum scores for three nasal symptoms during the late peak pollen season. Patients with add-on treatment for pollinosis (group B) were divided into those receiving add-on pranlukast therapy (group B1) and those receiving add-on H1 receptor agonist therapy (group B2). Nasal symptom scores in the late peak period were compared between the two subgroups. Data are presented as the mean ± standard error of the mean.